Safety and Efficacy of Microwave Ablation for Hepatocellular Carcinoma in the Setting of Transjugular Intrahepatic Portosystemic Shunt.
Hepatocellular carcinoma (HCC)
Microwave ablation (MWA)
Transjugular intrahepatic portosystemic shunt (TIPS)
Journal
Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
07
05
2021
accepted:
04
10
2021
pubmed:
4
12
2021
medline:
22
4
2022
entrez:
3
12
2021
Statut:
ppublish
Résumé
This retrospective analysis reviews five patients with transjugular intrahepatic portosystemic shunt (TIPS) who underwent percutaneous microwave ablation of hepatocellular carcinoma between January 2017 and September 2020. Mean tumor diameter was 2.0 cm (range 1.3-2.9 cm), and mean tumor distance from TIPS was 2.3 cm (range 1.5-3.3 cm). There were no major adverse events, and the TIPS patency was 100% post-ablation. The technical success rate was 100%, and the complete response rate was 100%. In this small study, percutaneous microwave ablation appears safe and effective for the treatment of hepatocellular carcinoma in patients with TIPS in the short-term follow-up period.
Identifiants
pubmed: 34859308
doi: 10.1007/s00270-021-03012-y
pii: 10.1007/s00270-021-03012-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
578-581Informations de copyright
© 2021. Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
Références
Yang JD, Hainaut P, Gores FJ, Amadou A, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.
doi: 10.1038/s41575-019-0186-y
El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.
doi: 10.1056/NEJMra1001683
Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers. 2019;11(8):1085.
doi: 10.3390/cancers11081085
Shiina S, Sato K, Tateishi R, et al. (2018). Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery. Can J Gastroenterol Hepatol. 4756147.
Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50.
doi: 10.1053/j.gastro.2004.09.014
Garcia-Pagan, et al. Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding. N Eng J Med. 2010;36:25.
Rajesh S, George T, Philips CA, et al. Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update. World J Gastroenterol. 2020;26(37):5561–96.
doi: 10.3748/wjg.v26.i37.5561
Kuo YC, Kohi MP, Naeger DM, et al. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol. 2013;36:1336–43.
doi: 10.1007/s00270-013-0698-8
Kohi MP, Fidelman N, Naeger DM, et al. Hepatotoxicity after transarterial chemoembolization and transjugular intrahepatic portosystemic shunt: do two rights make a wrong? J Vasc Interv Radiol. 2013;24:68–73.
doi: 10.1016/j.jvir.2012.08.032
Padia SA, Chewning RH, Kogut MJ, et al. Outcomes of locoregional tumor therapy for patients with hepatocellular carcinoma and transjugular intrahepatic portosystemic shunts. Cardiovasc Intervent Radiol. 2015;38(4):913–21.
doi: 10.1007/s00270-014-1009-8
Qiu B, Zhao MF, Yue ZD, et al. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension. World J Gastroenterol. 2015;21(43):12439–47.
doi: 10.3748/wjg.v21.i43.12439
Park J, Al-Tariq QZ, Zaw TM, R SS, Lu DSK. Radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. Cardiovasc Intervent Radiol. 2015;38:1211–7.
doi: 10.1007/s00270-015-1050-2
Izzo F, Granata V, Grassi R, et al. Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update. Oncologist. 2019;24(10):e990–1005.
doi: 10.1634/theoncologist.2018-0337
Liu W, Zheng Y, He WY, et al. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Aliment Pharmacol Ther. 2018;48(6):671–81.
doi: 10.1111/apt.14929
Poggi G, Tosoratti N, Montagna B, Picchi C. Microwave ablation of hepatocellular carcinoma. Wor J Hep. 2015;7(25):2578–9.
doi: 10.4254/wjh.v7.i25.2578